131488-15-8

Basic information

• Product Name: (-)-2-BETA-CARBOMETHOXY-3-BETA-(4-FLUOROPHENYL)NORTROPANE
• Synonyms: 2-BETA-CARBOMETHOXY-3-BETA-(4-FLUOROPHENYL)-8-AZABICYCLO[3.2.1]OCTANE;(-)-2-BETA-CARBOMETHOXY-3-BETA-(4-FLUOROPHENYL)NORTROPANE;8-AZABICYCLO[3.2.1]OCTANE-2-CARBOXYLIC ACID, 3-(4-FLUOROPHENYL), METHYL ESTER, (1R, 2S, 3S, 5S);NOR-BETAFT;NOR-BETA-CFT;NOR-2-CFT;NOR-WIN 35428
• CAS NO: 131488-15-8
• Molecular Formula: C15H18FNO2
• Molecular Weight: 263.31
• Mol File: 131488-15-8.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 355.2°C at 760 mmHg
• Flash Point: 168.6°C
• Appearance: /
• Density: 1.17g/cm³
• Vapor Pressure: 3.19E-05mmHg at 25°C
• Refractive Index: 1.526
• CAS DataBase Reference: (-)-2-BETA-CARBOMETHOXY-3-BETA-(4-FLUOROPHENYL)NORTROPANE(CAS DataBase Reference)
• NIST Chemistry Reference: (-)-2-BETA-CARBOMETHOXY-3-BETA-(4-FLUOROPHENYL)NORTROPANE(131488-15-8)
• EPA Substance Registry System: (-)-2-BETA-CARBOMETHOXY-3-BETA-(4-FLUOROPHENYL)NORTROPANE(131488-15-8)

Safety Data

• Hazardous Substances Data: 131488-15-8(Hazardous Substances Data)

Usage

General Description

(-)-2-BETA-CARBOMETHOXY-3-BETA-(4-FLUOROPHENYL)NORTROPANE is a chemical compound that is a derivative of the stimulant drug cocaine, and has been studied for its potential applications in medicine and research. It is a highly potent dopamine reuptake inhibitor, meaning that it can increase levels of dopamine in the brain, which may have implications for treating conditions involving dopamine dysfunction, such as Parkinson's disease and attention deficit hyperactivity disorder (ADHD). The compound has also been investigated for its potential use in treating addiction to cocaine and other stimulants, as it may have less addictive and rewarding properties compared to cocaine itself. Additionally, it has been studied in the field of positron emission tomography (PET) imaging for its ability to bind to dopamine transporters in the brain, which can provide valuable insights into brain function and disorders.

InChI:InChI=1/C15H18FNO2/c1-19-15(18)14-12(8-11-6-7-13(14)17-11)9-2-4-10(16)5-3-9/h2-5,11-14,17H,6-8H2,1H3/t11?,12?,13-,14?/m1/s1

Upstream product

• 50370-59-7 2β-carbomethoxy-3β-(4-fluorophenyl)tropane 
• 43021-26-7 methyl 8-methyl-8-azabicyclo[3.2.1]oct-2-ene-2-carboxylate 
• 352-13-6 4-flourophenylmagnesium bromide 
• 157008-48-5 (1R)-N-methyl-2β-methoxycarbonyl-3α-(4-fluorophenyl)-8-azabicyclo[3.2.1]octane 
• 50-36-2 Cocaine 
• 50373-10-9 methyl ecgonidine 
• 481-37-8 ecgonine 
• 484-93-5 ecgonidine 
• 303733-95-1 N-(2,2,2-trichloroethylcarbamoyl)-2β-carbomethoxy-3β-(4'-fluorophenyl)nortropane 

Relevant articles and documents

BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF

Bolaamphiphilic compounds are provided according to formula (I); where HG1, HG2 and L1 are as defined herein. Provided bolaamphiphilic compounds and the pharmaceutical compositions thereof are useful for delivering GDNF or NGF into animal or human brain.

Synthesis, structural identification, and ligand binding of tropane ring analogs of paroxetine and an unexpected aza-bicyclo[3.2.2]nonane rearrangement product

The structural requirements for high affinity at the serotonin transporter (5-HTT) have been investigated through the preparation of rigid paroxetine analogs. Tropane-derived analogs (4a-i) of paroxetine (2) were designed and synthesized as potential inhibitors of serotonin reuptake based on the structural and biological similarity between the two compound classes. Overall, the affinity of tropane-derived analogs at the 5-HTT was found to be at least an order of magnitude lower than that of paroxetine and ranged from 2-400 nM. The reduced affinity at the 5-HTT may be attributed to the inability of the rigid tropane-derived analogs to adopt conformations favored by the 5-HTT. Within the series of tropane analogs, the 2β,3β- and 2β,3α-isomers, 4a and 4d, were the most potent at the DAT and NET and are also significantly more potent than paroxetine (2) suggesting that their reduced conformational flexibility maximizes residence time in conformations favored by these transporters. Examination of the previously published preparation and structural assignment of 4a by additional NMR and X-ray crystallographic data has established that nucleophilic addition to the intermediate 2β- methanesulfonyloxymethyl-3β-(4-fluorophenyl)tropane unexpectedly provided the aza-bicyclo[3.2.2]nonane derivative 10a.

Therapeutic compounds

This invention to antagonists that inhibit transporters and receptors. The invention also relates to partial inhibitors of transporters and receptors that allow partial transport or partial binding of a compound to the transporter or receptor. The inventi